Please login to the form below

Not currently logged in
Email:
Password:

David Meek leaves Novartis to join Endocyte as first chief commercial officer

Joins shortly after major oncology deal with Merck & Co

US biopharma company Endocyte has appointed Novartis' David Meek to the newly created role of chief commercial officer.

Meek leaves Novartis after more than seven years at the Swiss pharma firm where he was most recently the head of northern and central Europe oncology.

Previously, he served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products, and he also served as the global business franchise head for Novartis' respiratory and dermatology franchise in Basel, Switzerland.

In his new role, Meek will be responsible for the development of Endocyte's commercial team and the company's overall commercial strategy and execution, which includes the deal with Merck & Co made in April, 2012, involving Endocyte's cancer drug vintafolide.

In addition to this drug, Endocyte's products in development include etarfolatide and other targeted small molecule drug conjugates.

"I'm very excited to join the Endocyte team, where I have been compelled by the company's approach to develop innovative therapies accompanied by companion diagnostics," said Meek.

Prior to his time at Novartis, Meek spent 15 years at Johnson & Johnson (J&J), where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

30th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Clarity of vision, insight and a thought-through strategic approach are our tools for delivering solutions that benefit our clients and...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...